← Back to Search

Monoclonal Antibodies

BMS-986446 Dose A for Alzheimer's Disease (TargetTau-1 Trial)

Phase 2

Recruiting

Research Sponsored by Bristol-Myers Squibb

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild AD dementia consistent with the National Institute on Aging and the Alzheimer's Association (NIA-AA) core clinical criteria

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up at week 76

Awards & highlights

TargetTau-1 Trial Summary

"This trial will test how well BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, works and how safe it is for people with early Alzheimer's Disease."

Who is the study for?

This trial is for individuals with early Alzheimer's Disease. Specific criteria for joining are not provided, but typically participants must meet certain health standards and may need to have a particular stage or form of the condition.Check my eligibility

What is being tested?

The study is testing BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, against a placebo to see if it's effective and safe in treating early Alzheimer's Disease.See study design

What are the potential side effects?

While specific side effects are not listed, monoclonal antibodies like BMS-986446 can sometimes cause reactions at the injection site, flu-like symptoms, allergic reactions, or other immune system-related issues.

TargetTau-1 Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have mild memory problems or mild Alzheimer's according to NIA-AA standards.

TargetTau-1 Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at week 76

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at week 76

This trial's timeline: 3 weeks for screening, Varies for treatment, and at week 76 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Mean change from baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score

Secondary outcome measures

Mean change from baseline in Alzheimer's Disease Assessment Scale-Cognitive subscale (ADASCog14) score

Mean change from baseline in Alzheimer's Disease Cooperative Study-instrumental Activities of Daily Living scale (ADCS-iADL) score

Mean change from baseline in Mini Mental State Examination (MMSE) score

+2 more

TargetTau-1 Trial Design

3Treatment groups

Experimental Treatment

Placebo Group

Group I: BMS-986446 Dose BExperimental Treatment1 Intervention

Group II: BMS-986446 Dose AExperimental Treatment1 Intervention

Group III: PlaceboPlacebo Group1 Intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

BMS-986446

2023

Completed Phase 1

~30

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor

2,641 Previous Clinical Trials

4,129,589 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are patients currently being accepted to participate in this clinical trial?

"As per clinicaltrials.gov, the current status of this medical trial is not open for recruitment. The initial posting date was 3/25/2024 while the latest update occurred on 2/13/2024. Despite this specific study being closed to enrollment, there are currently 549 other trials actively seeking participants."

Answered by AI

Are individuals who are above the age of 45 eligible to participate in this medical trial?

"To be considered for this research undertaking, candidates must fall within the age bracket of 50 to 80. Notably, there are a total of 14 trials designated for individuals under 18 and 539 geared towards those over the age of 65."

Answered by AI

At present, how many locations are hosting this particular clinical trial?

"Patients are being recruited at various research sites, including MD First Research in Chandler, California; Xenoscience Inc. - 21st Century Neurology in Phoenix, Connecticut; and the practice of Allan M. Block, MD in Gilbert, Colorado. Additionally, there are 171 more locations participating in patient recruitment for this trial."

Answered by AI

Is Dose A of BMS-986446 considered safe for human use?

"In this Phase 2 trial, the safety rating for BMS-986446 Dose A is placed at a level of 2 by our team at Power. This indicates that while there exists data supporting its safety profile, efficacy data is not yet available."

Answered by AI

Would it be possible for me to participate in this medical study?

"Patients aged between 50 and 80 years old with a diagnosis of Alzheimer's disease are eligible for participation in this clinical trial, which aims to recruit 475 individuals."

Answered by AI

Who else is applying?

What site did they apply to?

ActivMed Practices & Research, Inc. - Methuen

ActivMed Practices & Research, Inc. - Portsmouth

What portion of applicants met pre-screening criteria?

Met criteria

Why did patients apply to this trial?

I have been on the standard Alzhiemer's medication rivastigmine for a few years but know this is only standard treatment and does not work to reverse or improve my condition. I am willing to try trial medications in hopes of helping to improve my condition and help further the research for all.

PatientReceived no prior treatments

Recent research and studies

clinicaltrials.govStudy

Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease

2024. "Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06268886.

All > Alzheimers Disease Dallas > Greensboro